SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trending due to a major contract win with the U.S. Space Force for suborbital launches, a development that highlights the company's growing role in national security and defense infrastructure. While the community is actively celebrating this validation of Rocket Lab's execution, the stock price remains heavily tethered to broader space sector volatility and the performance of larger peers, leading to mixed sentiment among investors frustrated by the muted market reaction to positive news.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors and the Duchenne muscular dystrophy community prepare for a high-stakes FDA advisory committee meeting to review the companys therapy for DMD cardiomyopathy. Discussions are focused on the clinical data supporting both skeletal and cardiac benefits, with the community actively lobbying for a broad label and bracing for volatility ahead of the panel's decision.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is currently facing intense community debate and market volatility as investors weigh the potential of the Tanbreez project against concerns regarding management transparency, recent tender bid controversies, and ongoing share dilution. While some investors view the company as a strategic, highly undervalued play for critical mineral independence, others remain skeptical, pointing to delays, confusing communication regarding the Kenya bid, and a history of underperforming expectations.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as investors debate the impact of newly launched market-moving APIs and the company's financial performance, while social sentiment remains heavily polarized by the political discourse surrounding the brand. Community discussion is dominated by intense debates over the efficacy of trade policies, ongoing geopolitical tensions, and the platform's role in political advocacy.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is surging after announcing a significant oversubscribed $53 million private placement that has sparked intense community interest and speculation regarding potential long-term value. Investors are actively debating the stock's massive volatility and the impact of the financing news, with many monitoring short interest and the sustainability of the current price momentum.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is experiencing volatility as investors weigh the potential for a ceasefire between the U.S. and Iran against reports of ongoing supply constraints and geopolitical tension. Community discussion is heavily focused on whether recent diplomatic developments are a genuine path to de-escalation or just temporary noise in a market structurally squeezed by tight crude inventories.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing significant volatility as investors weigh disappointing monthly prescription data against upcoming regulatory and reimbursement catalysts, including the effective date for the permanent billing code and an imminent European decision. The community is actively debating the impact of competitive drug trial data while speculating that institutional players may be utilizing the share price decline to accumulate positions ahead of expected milestones.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as community members rally behind its position as a leader in real-world asset (RWA) tokenization, with many investors anticipating long-term growth driven by institutional interest and upcoming regulatory milestones. While bullish sentiment dominates the discussion regarding its utility and potential for a significant bull run, some participants emphasize the importance of monitoring governance proposals and potential supply shifts that could influence the asset's trajectory.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending amid investor volatility following a conservative full-year revenue outlook and a recent earnings miss, with the community actively debating whether the dip represents a long-term buying opportunity or a sign of persistent execution challenges. While discussions focus on aggressive sales team expansion and the long-term potential of the Vevye and Iheezo product lines, investors are closely watching for signs that management can better align messaging with actual financial results.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following an agreement with AT&T to expand the use of its quantum computing technology for network optimization and agentic AI tools. The community is actively debating the company's long-term commercial potential and valuation, with discussions frequently comparing it to other quantum peers as investors analyze the broader sector impact of recent government quantum-focused initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GraniteShares ETF Trust - GraniteShares Autocallable MARA ETF

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

MRAGraniteShares ETF Trust - GraniteShares Autocallable MARA ETF

Fundamentals

Latest MRA News